First AD

Second AD

Use of Combination Regimens in Frontline RCC

Please review data supporting the use of other combination regimens in frontline RCC.

CheckMate 214 (nivo +ipi): Tannir, et al. ASCO GU 2024. Abstract 363

KEYNOTE 426 (axi +pembro): Plimack ER, et al. Eur Urol. 2023)

CLEAR (len+pem vs sunitinib): Viktor Grunwald et. al, ASCO 2024, Abstract 4524 

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Video Series

My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC  

Martin H. Voss, MD, presents data supporting the use of various combination regimens in the frontline treatment of renal cell carcinoma (RCC), focusing on the pivotal trials such as CheckMate 214, KEYNOTE 426, and the CLEAR trial, emphasizing their respective efficacy, safety, and overall impact on the current treatment landscape for RCC patients. 

Use of Combination Regimens in Frontline RCC 